- Home
- MDWD vs NRO Comparison
MDWD vs NRO Comparison
Compare MDWD & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- NRO
- Stock Information
- Founded
- MDWD 2000
- NRO 2003
- Country
- MDWD Israel
- NRO United States
- Employees
- MDWD N/A
- NRO N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- NRO Finance/Investors Services
- Sector
- MDWD Health Care
- NRO Finance
- Exchange
- MDWD Nasdaq
- NRO Nasdaq
- Market Cap
- MDWD 172.6M
- NRO 187.8M
- IPO Year
- MDWD 2014
- NRO N/A
- Fundamental
- Price
- MDWD $16.48
- NRO $3.84
- Analyst Decision
- MDWD Strong Buy
- NRO
- Analyst Count
- MDWD 1
- NRO 0
- Target Price
- MDWD $28.00
- NRO N/A
- AVG Volume (30 Days)
- MDWD 46.6K
- NRO 239.4K
- Earning Date
- MDWD 11-26-2024
- NRO 01-01-0001
- Dividend Yield
- MDWD N/A
- NRO 11.41%
- EPS Growth
- MDWD N/A
- NRO N/A
- EPS
- MDWD N/A
- NRO N/A
- Revenue
- MDWD $20,141,000.00
- NRO N/A
- Revenue This Year
- MDWD $30.16
- NRO N/A
- Revenue Next Year
- MDWD $18.44
- NRO N/A
- P/E Ratio
- MDWD N/A
- NRO N/A
- Revenue Growth
- MDWD N/A
- NRO N/A
- 52 Week Low
- MDWD $8.41
- NRO $2.51
- 52 Week High
- MDWD $24.00
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- MDWD 44.78
- NRO 43.35
- Support Level
- MDWD $15.53
- NRO $3.71
- Resistance Level
- MDWD $16.85
- NRO $3.84
- Average True Range (ATR)
- MDWD 0.69
- NRO 0.09
- MACD
- MDWD -0.07
- NRO -0.01
- Stochastic Oscillator
- MDWD 32.87
- NRO 31.48
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.